November 8, 2017:
Mylan Australia is experiencing a temporary shortage of EpiPen® Jr 150mcg adrenaline (epinephrine) autoinjectors. This supply disruption is due to an unforeseen delay in supply from the overseas manufacturer. In the meantime, to minimise the impact on patient care, Mylan has put a process in place to ensure those most at-risk have access to emergency supply.
Mylan Australia wishes to advise that they will be supplying eligible patients with an EpiPen® Jr, expiring on 30 November 2017, at no charge.
Requests will only be accepted for patients requiring an EpiPen® Jr before the end of the month and who do not have access to another in-date EpiPen® Jr. This is a temporary solution until regular supply returns to the Australian market.
Patients can obtain supply by contacting their pharmacy. Pharmacists should then contact the Mylan Customer Support team on 1800 274 276 to request an EpiPen® Jr (expiring on 30 November 2017) that will be supplied to the pharmacy and patient at no charge.
Patients will need to return to their pharmacy with their prescription to replace the EpiPen® Jr at the end of November. Mylan expects stock to be available mid-to-late November 2017.
ASCIA recommends EpiPen® Jr 150mcg for patients weighing between 10-20kgs and EpiPen® 300mcg for patients 20kgs and over.
Pharmacists with any issues regarding supply of EpiPen® Jr or EpiPen® should contact the Mylan Customer Support team on 1800 274 276.
Please note that New Zealand is not affected by this temporary shortage.
For further information about anaphylaxis go to www.allergy.org.au/anaphylaxis